(Q45192026)

English

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

author name string

Raedler A

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Behrens C

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Bias P

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

11-12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1353-1363

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Drug therapy of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Colorectal cancer prevention in ulcerative colitis: a case-control study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02282.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2004.02282.X

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45192026&oldid=2081745495"